Analysis
Relationships with the drug industry: More regulation, greater transparency
BMJ 2009; 338 doi: https://doi.org/10.1136/bmj.b211 (Published 04 February 2009) Cite this as: BMJ 2009;338:b211- Harlan M Krumholz, Harold H Hines Junior professor of medicine and epidemiology and public health12,
- Joseph S Ross, assistant professor34
- 1 Section of Cardiovascular Medicine and Robert Wood Johnson Clinical Scholars Program, Department of Medicine, Section of Health Policy and Administration, School of Public Health, Yale University School of Medicine, PO Box 208088, New Haven, CT 06520-8088, USA
- 2Yale-New Haven Hospital Center for Outcomes Research and Evaluation, New Haven, CT, USA
- 3Department of Geriatrics and Adult Development, Mount Sinai School of Medicine, New York, USA
- 4James J Peters VA Medical Center, Bronx, New York, USA
- Correspondence to: H M Krumholz harlan.krumholz{at}yale.edu
The relationship between drug and device companies, the medical profession, and the public is at a critical juncture. Individuals who have placed their interests in profit and influence over patients and public health have overshadowed much of the good work and reputations of those who have engaged in constructive interaction.1 As a result, public perception of the drug industry, doctors …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.